Ms Gillian Smith

Consultant Urologist


Ms Gillian Smith was appointed to the Royal Free in 2005 and is the Divisional Director of Transplantation and Specialist Services.

Gillian has a specialist interest in diagnosing and treating prostate disease and is expert in providing men with suspected prostate cancer with a rapid and accurate diagnosis. Over the past decade, she has established a multidisciplinary specialist prostate team.

Through a collaborative approach between experts in different specialties, this team now provides high quality prostate assessment at three of the Royal Free’s hospital sites. Using her experience, Gillian is currently working with a number of other hospitals and partners to expand modern prostate cancer diagnostic services across north London.

Gillian also runs an active surveillance clinic for men with low risk prostate cancer, in which she ensures that all patients benefit from the most up to date imaging and biopsy techniques to guide their management and provide reassurance that surveillance is the correct approach.

Gillian is dedicated to education and training in urology at a national level. Through her work with the Intercollegiate Board in Urology, she has promoted and maintained high standards in UK urology.

Gillian’s current research interests are in improving the accuracy and experience of prostate cancer diagnosis for patients.


  • Urology

Clinical Interests

  • Prostate cancer
  • Prostate diagnosis and assessment
  • General urology

Procedures Offered

  • Prostate assessment, including biopsy

Cohen D, Roy A, McCarthy F, Goode A, Train M, Marcus A, Grant, L, Smith G, Singh P.

One-stop prostate clinic incorporating same-day multiparametric prostate MRI and prostate biopsies: initial experience and impact on pathway compliance.

BJUI 2017; In press

Dinneen E, Gresty H, Goode A, Train M, Grant, L, Marcus A, Smith G, Singh P

MRI/TRUS fusion prostate biopsy: can we omit concurrent systematic biopsies?

BJUI 2017; In press

Undre S, Sevdalis N, McDermott J, Giddie J, Dinner L, Smith GL

Interruptions, teamwork and safety in the operating room: a prospective quantitative study in urological surgery

European Urology 2011; Suppl 10: 110

Peer-reviewed publications

The impact of intraoperative distractions on patient safety: a prospective descriptive study using validated instruments

Sevdalis N, Undre S, McDermott J, Giddie J, Dinner L, Smith GL

World Journal of Surgery; 2014 Apr;38(4):751-8

Comment on: The national burden of infections after prostate biopsy in England and Wales: a wake up call for better prevention

Balakrishnan I, Smith G

Journal of Antimicrobial Chemotherapy 2013; Oct; 68(10): 2418-9

MD Thesis. The role of insulin-like growth factor binding protein-3 in metastatic prostate cancer, and its potential as a therapeutic target.

Smith GL

University of London 2003.

Quantification of human telomerase reverse transcriptase mRNA in testicular germ cell tumors by quantitative real-time RT-PCR.

Schrader M, Burger AM, Muller M, Krause H, Straub B, Smith GL, Newlands ES, Miller K.

Oncol Rep 2002; 9: 1097-1105.

Association of ErbB2 Ser-1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer.

Ouyang X, Gulliford T, Zhang H, Smith GL, Huang G, Epstein RJ.

Molecular and Cellular Biochemistry 2001; 218: 47-54.

Dual x-ray absorptiometry detects disease- and treatment-related alterations of bone density in prostate cancer patients.

Smith GL, Doherty AP, Banks LM, Dutton J, Hanham IW, Christmas TJ, Epstein RJ.

Clinical and Experimental Metastasis 2000;18: 385-90.

Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.

Doherty AP, Bower M, Smith GL, Miano R, Mannion EM, Mitchell H, Christmas TJ.

Br J Cancer 2000; 83: 1432-1436.

Inverse relationship between prostate-specific antigen (PSA) and insulin-like growth factor-binding protein 3 (IGFBP3) in bone metastases and serum of prostate cancer patients.

Smith GL, Doherty AP, Mitchell H, Hanham IW, Christmas TJ, Epstein RJ.

Lancet 1999; 354: 2053-2054.

Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: implications for paracrine growth.

Doherty A, Smith GL, Banks L, Christmas TJ, Epstein RJ.

J Pathology 1999; 188: 278-281.

Book chapters

Obstructive Uropathy

Smith G, Harber M

In Harber M ed., Practical Nephrology.

London: Springer. 2014.

Upper Urinary Tract and Lower Urinary Tract

Smith G, Pridgeon S

In Novell R, Baker D, Goddard N ed., Kirk’s General Surgical Operations.

London: Elsevier. 2013.

Like to book an appointment?

Fill out the contact form below or call us on
020 7317 7751 to speak with a member of our team

020 7317 7751 Book a Consultation